Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Hard Capsules 28 X 12.5 |
|
15971 | 23880 |
|
Hard Capsules 28 X 25 mg |
|
15972 | 23882 |
|
Hard Capsules 28 X 50 mg |
|
15976 | 23883 |
Related information
Dosage
For GIST and MRCC, the recommended dose of Sunitinib is 50 mg taken orally once daily, for 4 consecutive weeks, followed by a 2-week rest period (Schedule 4/2) to comprise a complete cycle of 6 weeks.
For pNET, the recommended dose of Sunitinib is 37.5 mg taken orally once daily without a scheduled rest period.
Please refer to the license holder for further details
Indications
Advanced Renal Cell Carcinoma
Gastrointestinal Stromal Tumor: after disease progression on or intolerance to imatinib mesylate.
Pancreatic Neuroendocrine Tumors (pNET): Treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pNET) with disease progression.
Contra-Indications
Hypersensitivity to erlotinib or to any of the excipients.
Special Precautions
Please refer to the license holder for further details.
Side Effects
Please refer to the license holder for further details.
Drug interactions
Please refer to the license holder for further details.
Pregnancy and Lactation
Please refer to the license holder for further details.
